SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001214659-22-008168
Filing Date
2022-06-17
Accepted
2022-06-17 16:57:39
Documents
1
Period of Report
2022-06-15

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT marketforms-56493.html 4  
1 PRIMARY DOCUMENT marketforms-56493.xml 4 3855
  Complete submission text file 0001214659-22-008168.txt   5232
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Issuer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences

Mailing Address C/O UROGEN PHARMA LTD. 9 HA'TA'ASIYA STREET RA'ANANA L3 4365007
Business Address
Barrett Elizabeth A. (Reporting) CIK: 0001764157 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38693 | Film No.: 221024731